These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11464883)

  • 1. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
    Fulda S; Fichtner I; Hero B; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
    Fulda S; Oster W; Berthold F
    Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.
    Renner S; Krümpelmann S; Bruchelt G; Wiesinger H; Niethammer D; Klingebiel T
    Anticancer Res; 2000; 20(6B):4531-8. PubMed ID: 11205300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
    Fichtner I; Lemm M; Becker M; Berthold F
    Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
    Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
    Borsi JD; Csaki C; Ferencz T; Oster W
    Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection by amifostine of cyclophosphamide-induced myelosuppression.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine and chemotherapy-related thrombocytopenia.
    Budd GT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma.
    Fuchs J; Wenderoth M; von Schweinitz D; Haindl J; Leuschner I
    Cancer; 1998 Dec; 83(11):2400-7. PubMed ID: 9840541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
    Fouladi M; Stempak D; Gammon J; Klein J; Grant R; Greenberg ML; Koren G; Baruchel S
    Cancer; 2001 Aug; 92(4):914-23. PubMed ID: 11550166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
    Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
    J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
    Capizzi RL; Scheffler BJ; Schein PS
    Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Budd GT; Ganapathi R; Bukowski RM; Murthy S
    Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of spontaneous metastases formation by amifostine.
    Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
    Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
    Johnson PW; Muers MF; Peake MD; Poulter KM; Gurney EM; Napp VV; Hepburn PM; Brown JM
    Br J Cancer; 2001 Jan; 84(1):19-24. PubMed ID: 11139307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
    Green D; Bensely D; Schein P
    Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.